Profile
Paul J.
Frohna worked as a Medical Director and Head of Clinical Pharmacology at Genentech and CV Therapeutics respectively from 2001 to 2006.
He then became a Professor at the University of Pennsylvania and The University of Texas at Austin.
Later, he worked as a Vice President of Clinical Development at FibroGen and as a Chief Medical Officer at ProFibrix BV.
Frohna holds a doctorate degree from the University of Pennsylvania and Georgetown University.
Former positions of Paul J. Frohna
| Companies | Position | End |
|---|---|---|
| FIBROGEN, INC. | Chief Tech/Sci/R&D Officer | 2006-12-31 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Corporate Officer/Principal | 2005-12-31 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2003-12-31 |
| The University of Texas at Austin | Corporate Officer/Principal | - |
| University of Pennsylvania | Corporate Officer/Principal | - |
Training of Paul J. Frohna
| University of Pennsylvania | Doctorate Degree |
| Georgetown University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Private companies | 3 |
|---|---|
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Paul J. Frohna